Shivom – a data discovery and analysis solutions platform – on Tuesday unveiled its second release – Alpha 2.O. Leveraging the latest advancements in blockchain and machine-learning technology, Shivom is optimising how DNA is shared, secured and analysed in order to bring exponential value to the genomics industry.
In November 2018, Shivom launched its first release amid great enthusiasm and fervour. Since then, the product and development teams have been working on fixing bugs and integrating new features that have come from their recent partnership with Lifebit. In its first release, it streamlined its UI/UX and USPs based on the need to innovate in the area of secure storage. It also had multiple new-age features such as simplified sign-up DNA upload & encryption, etc.
Continuing its efforts in the area of innovation, Shivom continued developing on the previous release and has now launched its second release – Alpha 2.O. The latest advancements in the platform include avatars, issuing of notifications, bug-fixing throughout the platform, enterprise search functionality, an upgraded UI, and finally our blockchain transaction and verification for DNA file-uploading.
With the above-mentioned substantial updates, the platform can now verify via blockchain when a file is uploaded, secured and encrypted via Shivom. The next release titled ‘MVP’ will set to deliver DNA sequencing kits, an integrated wallet, marketplace and secure-sharing features. With a successful and well-tested second release, Shivom is steering itself into capturing a mega segment in this market.
About Shivom Shivom is a biotechnology data and analysis company optimising the way DNA is shared, secured and analysed. By utilising innovative technologies and pharmaceutical companies with the ability to securely share, store and analyse DNA data quickly, efficiently and at any scale. such as blockchain and machine-learning algorithms, we are able to democratise genomics. Doing so, we empower data-owners, researchers To learn more about the project, visit the Shivom website.
The M35 100-metre world sprint champion Lion Martinez joined Shivom Innovation Council (SIC) on February 1, 2019. Shivom is a biotechnology data and analysis company optimising the way DNA is shared, secured and analysed. It leverages innovative technologies such as blockchain and machine-learning algorithms to democratise genomics.
Lion joining SIC marks the very first steps of Shivom into building a sport, athletics and wellbeing initiative. The sports initiative will use state-of-the-art genomics and AI algorithms to develop science-based programmes to make people fitter and perform on a higher level. The programme seeks to identify from genetic bases as to what makes an athlete an, in turn, this data into meaningful insight for sports and fitness individuals who are interested in trying innovative and evidence-based training programmes to improve their efficiencies. With his experience in athletics, Lion will play a key role in strategising on the same.
SIC is an internal think tank at Shivom which supports and guides the senior management on the latest technologies, industry trends and strategies. It includes expert scientists, groundbreaking healthcare solution-providers, cybersecurity pioneers and genomics researchers. The council includes the likes of Taavi Roivas, former prime minister of Estonia and Antanas Guoga, a Lithuanian representative at the European Parliament. With Lion coming onboard, Shivom plans to foray into sports and wellbeing soon.
Lion, who in his own words “likes cooking, gaming and toast”, has 20 years of experience in marketing, and brand and product management. He professional endeavours include working in various capacities with global companies such as Electronic Arts, Disney, Warner Brothers, Asus and Sony, among several others. Lion is presently the Global Product Manager of e-sport software company Wasder AB.
A former national and European-level athlete, Lion has numerous national gold medals (in 100-metre sprint) in his kitty. He was also the youngest-ever Swedish to have participated in the 2002 European Championships in Munich. Lion holds a 100-metre world championship gold medal (2016) and has numerous records and medals (in 60, 100 and 200-metre sprints) to his credit. Additionally, he has been involved in coaching, public speaking and widespread health issues and initiatives over the past 20 years, engaging with children, youth, adults and senior citizens alike. We believe he will become the torchbearer of the planned sports initiatives at Shivom.
About Shivom Shivom is a biotechnology data and analysis company optimising the way DNA is shared, secured and analysed. By utilising innovative technologies such as blockchain and machine-learning algorithms, we are able to democratise genomics. Doing so, we empower data-owners, researchers and pharmaceutical companies with the ability to securely share, store and analyse DNA data quickly, efficiently and at any scale. For further information, please visit: https://shivom.io/
How often have you come across a patient of cervical cancer around you? Chances are, rarely. But reality begs to differ. According to the World Health Organisation (WHO), over six per cent women around the world (including 570,000 new cases) suffered from cervical cancer in 2018. Sadly, the statistics of both the developed and developing countries tell a similar horrifying story. Every day, nine women in the UK are diagnosed with cervical cancer and three lose their battles to life. In the US, nearly 13,000 women are diagnosed with cervical cancer every year, which amounts to an appalling 36 women falling prey every day! Developing countries like India have morbid statistics too. As per a study by National Center for Biotechnology Information, India alone accounts for a quarter of cervical cancer cases globally. Approximately 270,000 women across the world die from cervical cancer yearly, with 85 per cent deaths occurring in low-to-middle income countries. Owing to the gigantic figures, the United States Congress designated January as the Cervical Health Awareness Month.
Most common among women aged around 35 years, cervical cancer has remained, through times, an ignominious reality. However, even more lamentable is the fact that 75 per cent of such cases are actually prevented by cervical screening (or smear tests) and vaccination. Yet, one in four women does not attend this potentially life-saving test because of embarrassment. Some time back as part of the Pink Chain campaign, a study among schoolteachers in India was conducted. It revealed that cervical cancer was the second most common cancer in India. It also identified and assessed the level and impact of awareness programmes in the adoption of safe practices in prevention and early detection. Uneasiness around discussing the topic with friends, family and peers emerged as the main reason behind women not coming forward for tests and treatment.
While cervical cancer rates have dropped significantly within the United States over the past few decades, it still remains a critical global health issue. The high mortality rate for cervical cancer in the developing world is driven by limited access to cervical cancer screening and treatment. Laboratory-based methods used to detect cervical cancer, and the personnel required to perform and analyse them may be unavailable in developing nations. In an alarming finding, it was identified that approximately 90 per cent of deaths from cervical cancer occurred in low- and middle-income countries. Likewise, the ability to treat cervical cancer is highly dependent on access to surgical facilities, chemotherapy agents and radiation equipment.
The high global mortality rate despite having mechanisms to diagnose and treat this cancer is a matter of great concern. Doctors and researchers have time and again emphasised that more awareness programmes need to be run and sustained in order to literate people, especially women, to combat this cancer. Women must be encouraged to speak, walk up to a doctor and get her diagnosed. Reduction in mortality could be induced through a comprehensive approach which includes preventive care, early diagnosis, effective screening and treatment, and follow-ups. Particularly, in countries where screening programmes are not available, identifying cervical cancer at an early stage and providing effective treatment can improve the likelihood of survival. Presently, in many low-income nations, the disease is often not identified until in advanced stages.
Widespread training and awareness programmes run by state governments in partnership with CSR divisions of private firms can also be a way forward in combating cervical cancer. They must be made educated on the initial symptoms of the cancer. WHO Package of Essential non-communicable (PEN) disease interventions for primary healthcare in low-resource settings has guidance on the approach to assessing and referring affected women in the primary care setting. This must be widely publicised through various broadcast channels. In one of its studies, the WHO has concluded that “… screening should be performed at least once for every woman in the target age group (30-49 years) when it is most beneficial; HPV testing, cytology and visual inspection with acetic acid (VIA) are all recommended screening tests; cryotherapy or loop electrosurgical excision procedure (LEEP) can provide effective and appropriate treatment for the majority of women who screen positive for cervical pre-cancer; “screen-and-treat” and “screen, diagnose and treat” are both valuable approaches.”
Irrespective of the approach being deployed in educating women, the key to an effective programme is reaching the largest proportion of women at risk. Organised screening programmes, comprehensive cervical cancer prevention and control, community education, social mobilisation, vaccination, etc. can go a long way in improving cervical cancer control. Cervical Health Awareness Month is an opportunity to dedicatedly work, for a whole month, towards ensuring that our women remain safe and prevented from this deadly cancer. Let us spread the word around, not only among our female friends but also among our male friends, peers and family so that in case of such diagnosis, every person around must be aware of the next critical steps involved in treating the patient. Let us all be well-equipped for a better tomorrow because prevention is certainly better than cure.
As 2018 draws to a close, the team at Shivom are incredibly proud of what we’ve accomplished in the past year, and look forward to progressing in our mission to build the world’s largest blockchain-based genomic data hub for years to come.
As those who have been supporting us know, we’ve come a long way from where we were this time last year. After closing an incredibly successful ICO, we’re proud to say that the OMX token is listed on four exchanges. We’ve assembled an impressive team and Innovation Council, restructured, the company’s leadership, redesigned our website and forged important partnerships, opened up an office in London, all whilst continuing to fine-tune the Shivom platform – in case you missed it, we released the Alpha last month, allowing users to securely upload DNA data and create a wallet which, beginning in Q1 2019, will allow them to monetise the sharing of this information with researchers and institutions.
You can look forward to a handful of other updates around that time. Our next release will integrate features such as Enterprise Search and analytic tools for pharmaceutical and healthcare organisations, to name a few.
In our ongoing goal to contribute to the fields of predictive and preventative medicine, Shivom in coordination with local partners have commenced with the development of clinical research pilot projects focused on the collection of DNA samples from those afflicted with sickle-cell disease and type-2 diabetes (in Sub-Saharan Africa and India, respectively). Both of these diseases are rampant in these regions, and while modern technologies allow for their diagnoses, they often go unnoticed. Alongside our partners, Genetic Technologies Limited,eMQT, and the local partners in India, we’ll rely on the Shivom platform to collect and store genomic information securely, before sequencing and analysing it, allowing researchers to devise better and more affordable treatments, both globally and in specific regions. Other partnerships formed this year include MeFy, Atana and SingularityNET both pioneers in the blockchain space.
In addition to our blockchain partnerships, we’re of course also thrilled to be working closely with our new London-based bioinformatics partner Lifebit. Lifebit are creating a cloud-based cognitive system, leveraging sophisticated machine learning algorithms to allow their software to draw powerful insights from genetic information.
We intend to integrate Lifebit’s ‘Deploit’ pipeline, which will allow users and organisations using the Shivom platform to perform analytics on their data automatically. Its widespread use by R&D departments and other players in healthcare is a testament to the quality of the insights derived from genomic information fed into the system. What this means for Shivom users is highly scalable, highly effective and near-instant analytics around the clocks. Shivom will provide presets for easy use, though tech-savvy users and businesses will have a wide variety of customisation options with Docker services.
In other news, we hope you caught the Advancements on CNBC on the 16th of December, where the world of blockchain technology was explored by Ted Danson, with a special feature on Shivom.
In other events, the team have been busy in this last quarter sharing the Shivom story across the globe. CSO Gourish Singla represented Shivom at the Malta Blockchain Summit and Slush Small Talks, India. COO DR Natalie Pankova and Marketing Director Nate Raine attended HealthCare Unblocked in London. The penultimate event of the year, the Digital Freedom Festival, saw CEO, Henry Ines give a keynote titled “The Future of Health: Reinvention of Healthcare & Wellness”
Where to find us next
We are already busy with plans for the start of the year with Henry Ines, CEO recently announced our exciting partnership with FMW Media Works, the parent Company of ‘NEW TO THE STREET’ and our appearance on their 12-month TV series ‘EXPLORING THE BLOCK’ which will air on the FOX Business Network. We look forward to sharing our journey to date as a health-tech startup and showcasing our genomics datahub and marketplace powered by blockchain and AI technology.
It’s been a busy and productive year. We’ve come a long way, and have no intention of slowing down anytime soon. None of our efforts would have been possible without the support of our vibrant community and backers, so we’d like to thank you all profusely for joining us on our mission.